GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oxurion NV (XBRU:OXUR) » Definitions » Gross-Profit-to-Asset %

Oxurion NV (XBRU:OXUR) Gross-Profit-to-Asset % : 0.13% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Oxurion NV Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Oxurion NV's annualized Gross Profit for the quarter that ended in Dec. 2023 was €0.01 Mil. Oxurion NV's average Total Assets over the quarter that ended in Dec. 2023 was €9.19 Mil. Therefore, Oxurion NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.13%.


Oxurion NV Gross-Profit-to-Asset % Historical Data

The historical data trend for Oxurion NV's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oxurion NV Gross-Profit-to-Asset % Chart

Oxurion NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.88 3.08 1.94 0.53 1.12

Oxurion NV Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.59 1.29 -0.32 1.65 0.13

Competitive Comparison of Oxurion NV's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Oxurion NV's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oxurion NV's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oxurion NV's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Oxurion NV's Gross-Profit-to-Asset % falls into.



Oxurion NV Gross-Profit-to-Asset % Calculation

Oxurion NV's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=0.104/( (11.993+6.55)/ 2 )
=0.104/9.2715
=1.12 %

Oxurion NV's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0.012/( (11.82+6.55)/ 2 )
=0.012/9.185
=0.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Oxurion NV Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Oxurion NV's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Oxurion NV (XBRU:OXUR) Business Description

Traded in Other Exchanges
Address
Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME). The Group's research and development facilities are located in Belgium .The Company is engaged in the development of drugs to treat back-of-the-eye diseases, more specifically, ophthalmologic pharmaceuticals to treat vascular retinal disorders, specifically DME.

Oxurion NV (XBRU:OXUR) Headlines

No Headlines